Alimera Sciences, Inc.
ALIM · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.51 | -0.14 | -0.24 | 0.19 |
| FCF Yield | 0.30% | -0.28% | 1.57% | -9.88% |
| EV / EBITDA | 125.00 | 493.87 | 72.24 | 39.62 |
| Quality | ||||
| ROIC | -0.06% | -1.74% | 0.55% | 1.41% |
| Gross Margin | 85.81% | 72.02% | 86.22% | 74.67% |
| Cash Conversion Ratio | -0.31 | 0.09 | -1.00 | 7.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.74% | 14.75% | 11.01% | 5.18% |
| Free Cash Flow Growth | 255.88% | -115.93% | 137.49% | 87.93% |
| Safety | ||||
| Net Debt / EBITDA | 21.20 | 107.04 | 13.76 | 14.29 |
| Interest Coverage | -0.02 | -0.62 | 0.15 | 0.90 |
| Efficiency | ||||
| Inventory Turnover | 1.11 | 1.52 | 1.93 | 1.57 |
| Cash Conversion Cycle | -35.05 | -83.61 | -39.99 | -14.30 |